Table 1.

Candidate targeted therapeutics for the dysfunctional p53 pathway in pancreatic cancers discussed in this section

Drug	Combination with	Comments
RITA	Gemcitabine, FOLFOX	Sensitizes resistant to gemcitabine and to FOLFOX cells
CP-31398	Gemcitabine	Sensitizes resistant to gemcitabine cells
PXN822	–	Restores p53 transcriptional activity
Nutlin 3a	Etoposide	Synergism in increasing DNA damage
Nutlin 3a	–	Effect on tumor micro-environment
Proteasome inhibitors	–	Theoretical interest in c-Myc amplified cancers
Chloroquine, hydroxychloroquine	+/– chemotherapy	No benefit in clinical trials but biomarkers of sensitivity such as p14 loss may be worth exploring
Rucaparib	Nutlin 3a, RG7388	Potential synergism in cancers with mutated p53
Olaparib	Pimasertib	Synergism in BRCA2 wildtype pancreatic cancer cells